Can I Take Ashwagandha with Praluent (Alirocumab)?

How Alirocumab Works and Why CYP450 Does Not Apply

Alirocumab is a fully human IgG1 monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9), preventing PCSK9 from degrading hepatic LDL receptors. More LDL receptors remain on the hepatocyte surface, pulling LDL-C out of circulation. The drug is cleared through two parallel routes: a saturable, target-mediated route at low concentrations and a non-saturable proteolytic degradation route at higher concentrations [1].

Because it never passes through the cytochrome P450 enzyme system, drugs or supplements that inhibit or induce CYP3A4, CYP2D6, or P-glycoprotein cannot meaningfully alter alirocumab plasma levels. The Praluent prescribing information lists no drug-drug interactions requiring dose adjustment [2]. This stands in contrast to statin co-administration scenarios, where CYP3A4 inhibitors can meaningfully raise simvastatin or atorvastatin concentrations.

What This Means for Supplement Users

The absence of CYP450 metabolism is the single most clinically useful fact for a patient asking about supplements with Praluent. Supplements that are strong CYP3A4 inhibitors, such as berberine or grapefruit-derived compounds, do not pose the same category of risk they would with a small-molecule statin. Ashwagandha (Withania somnifera) root extract is not a clinically significant CYP enzyme inhibitor at typical oral doses of 300-600 mg/day [3].

The Remaining Question: Pharmacodynamic Overlap

Even without a pharmacokinetic interaction, two agents can influence the same physiological endpoint. Ashwagandha has documented effects on LDL cholesterol, triglycerides, thyroid hormones, and cortisol. Each of those effects could theoretically modify how a patient responds to or tolerates alirocumab therapy.

Ashwagandha's Evidence Base for Lipid Effects

Ashwagandha modestly lowers LDL-C and total cholesterol in human trials, though effect sizes are small compared with PCSK9 inhibitor therapy. In a double-blind RCT published in Medicine (2023) involving 98 participants receiving 600 mg/day of ashwagandha root extract for 8 weeks, LDL-C fell by 9.7% and total cholesterol by 6.8% from baseline [4]. A 2019 randomized study (N=50) in the Journal of the International Society of Sports Nutrition demonstrated LDL-C reductions of approximately 7% after 8 weeks of 600 mg KSM-66 extract [5].

These reductions are mechanistically different from PCSK9 inhibition. Ashwagandha's lipid-lowering activity appears to reflect withanolide-mediated suppression of cholesterol biosynthesis and possibly thyroid hormone upregulation, which increases LDL receptor expression through a pathway separate from PCSK9 [6].

Does Additive LDL Lowering Create a Risk?

Patients on alirocumab already achieve LDL-C reductions of 46-61% in long-term trials [7]. Adding a 9-10% further reduction from ashwagandha could theoretically push LDL-C below 25 mg/dL in patients who are already near target. Very low LDL-C levels below 15-20 mg/dL have been studied extensively; the FOURIER trial (N=27,564) and ODYSSEY OUTCOMES (N=18,924) found no increase in adverse events at LDL-C levels as low as 15-20 mg/dL over median follow-up periods of 2.2 and 2.8 years respectively [8]. The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction states: "Available evidence does not suggest harm at very low achieved LDL-C levels for patients on maximally tolerated lipid-lowering therapy" [9].

Still, tracking LDL-C after adding any supplement to an existing Praluent regimen is sensible clinical practice.

Triglyceride and HDL Effects

Ashwagandha root extract also reduces triglycerides modestly, by roughly 14-18% in the same 2019 study (N=50) cited above [5]. Alirocumab produces a triglyceride reduction of approximately 13-17% as a secondary endpoint in ODYSSEY LONG TERM [7]. The combination may produce additive triglyceride lowering. For patients with baseline hypertriglyceridemia, this is more benefit than concern, but it is worth documenting at a follow-up lipid panel.

Ashwagandha's Thyroid Effects and Why They Matter

Documented T3 and T4 Elevation

Several clinical studies show that ashwagandha root extract raises serum triiodothyronine (T3) and thyroxine (T4) in euthyroid and subclinically hypothyroid individuals. A randomized, double-blind trial published in the Journal of Alternative and Complementary Medicine (2018) using 600 mg/day of root extract for 8 weeks in 50 adults with subclinical hypothyroidism reported significant increases in T3 (41.5% from baseline) and T4 (19.6% from baseline), with TSH decreasing toward normal range [10].

Thyroid hormones increase LDL receptor expression on hepatocytes independently of PCSK9 pathways. A patient whose thyroid function improves meaningfully after starting ashwagandha may show an additional 5-15% LDL-C reduction through this indirect mechanism [6]. This is an additive effect that requires no dose adjustment to alirocumab itself, but does warrant a repeat lipid panel.

Patients Already on Levothyroxine

Patients taking levothyroxine alongside Praluent form a specific subgroup that needs attention. If ashwagandha raises endogenous thyroid hormone production, levothyroxine dosing may require downward adjustment. The American Thyroid Association recommends TSH monitoring 6-8 weeks after any change in thyroid hormone status [11]. Adding ashwagandha in this setting should be disclosed to the prescribing endocrinologist or internist.

Patients Who Are Euthyroid

For patients with normal thyroid function, the magnitude of T3/T4 change from ashwagandha is unlikely to produce clinical hyperthyroidism at doses of 300-600 mg/day. A baseline TSH before starting and a repeat at 8-12 weeks is a reasonable precaution.

Cortisol Modulation and Cardiovascular Relevance

Ashwagandha is classified as an adaptogen and its most consistent human trial data concerns cortisol reduction. A double-blind, placebo-controlled trial in Medicine (2019) involving 60 adults receiving 240 mg/day of ashwagandha extract showed a 23% reduction in morning serum cortisol at 60 days (P<0.001) [12].

Why Cortisol Matters for Patients on PCSK9 Inhibitors

Patients prescribed alirocumab typically have familial hypercholesterolemia or established ASCVD, both conditions associated with elevated cardiometabolic stress. Chronic cortisol elevation raises LDL-C and triglycerides, reduces HDL-C, and promotes visceral adiposity. Reducing cortisol through ashwagandha may therefore contribute to the lipid-lowering effect noted above. This represents a plausible indirect pharmacodynamic mechanism, not a drug-drug interaction in any pharmacokinetic sense.

No published trial has directly studied cortisol-mediated LDL changes in patients on PCSK9 inhibitors, and this remains an area where further research is needed.

Testosterone Effects: Relevant for Some Alirocumab Patients

Alirocumab is often used by middle-aged and older men with ASCVD. This demographic also frequently considers testosterone support through supplements. Ashwagandha has modest evidence for raising free testosterone. A randomized controlled trial in Fertility and Sterility (2010) involving 75 infertile men showed significant increases in serum testosterone (17% from baseline) after 90 days of 5 g/day root powder [13].

At the more common 300-600 mg extract dose, testosterone effects are smaller but still measurable. A 2015 RCT in the Journal of the International Society of Sports Nutrition (N=57) showed free testosterone increased by 15.0% in the ashwagandha group vs. 2.5% in placebo at 8 weeks [14].

Testosterone itself modulates lipid metabolism. Higher free testosterone is associated with modestly lower LDL-C and triglycerides in population studies. This adds one more indirect pathway through which ashwagandha could augment the lipid-lowering seen with alirocumab.

Liver Safety: An Underappreciated Consideration

Ashwagandha and Hepatotoxicity Reports

Rare cases of ashwagandha-associated liver injury have been published. A 2023 case series in the American Journal of Medicine described seven patients with acute hepatocellular liver injury temporally linked to ashwagandha supplementation; all resolved after discontinuation [15]. The mechanism is unclear but may involve withanolide-mediated mitochondrial stress.

Alirocumab and Hepatic Monitoring

Alirocumab does not require routine liver function monitoring under its FDA label, and ODYSSEY LONG TERM reported no significant hepatotoxicity signal over 78 weeks [7]. However, patients combining alirocumab with high-dose statins (a common regimen) already carry a small statin-related transaminase risk. Adding ashwagandha to that combination warrants a baseline ALT/AST before starting and a recheck at 8-12 weeks.

When to Stop

If ALT or AST rises above 3 times the upper limit of normal, ashwagandha should be discontinued first, given the existing case reports of supplement-related hepatotoxicity, and hepatic function retested at 4-6 weeks.

Drug Interaction Classification Framework

The table below organizes the ashwagandha-alirocumab relationship across four interaction domains. No published interaction database, including Natural Medicines Comprehensive Database and the Lexicomp system, assigns a contraindication rating to this combination. The Natural Medicines database currently rates the evidence for ashwagandha-lipid interactions as "possibly effective" with a "C" interaction rating for most cardiovascular medications.

| Interaction Domain | Mechanism | Clinical Significance | Action Required | |---|---|---|---| | Pharmacokinetic (CYP450) | None. Alirocumab is not CYP metabolized. | None | None | | LDL-C pharmacodynamic | Additive lowering via withanolide and cortisol pathways | Low to moderate | Repeat lipid panel at 8-12 weeks | | Thyroid hormone | Ashwagandha may raise T3/T4 by 10-40% | Moderate in hypothyroid patients | Baseline and follow-up TSH | | Hepatic safety | Rare ashwagandha hepatotoxicity; alirocumab is hepatically benign | Low but non-zero | Baseline and follow-up ALT/AST |

What the Guidelines Say About Supplements and PCSK9 Inhibitors

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol does not specifically address ashwagandha. It does state that "clinicians should ask about all dietary supplement use at each visit, as several supplements may affect lipid metabolism or interact with prescribed therapies" [9]. The American College of Cardiology recommends against substituting supplements for proven pharmacotherapy in high-risk ASCVD patients [9].

In practice, that means ashwagandha may be used alongside alirocumab, but it should not replace it. Patients who discontinue alirocumab in favor of supplements alone face substantial residual cardiovascular risk. ODYSSEY OUTCOMES demonstrated a 15% relative reduction in major adverse cardiovascular events (MACE) with alirocumab vs. Placebo over 2.8 years (hazard ratio 0.85, 95% CI 0.78-0.93, P<0.001) [8].

Practical Clinical Guidance: What to Do If You Are Already Taking Both

Most patients who discover they are already taking ashwagandha alongside Praluent do not need to panic. The combination is not contraindicated. Stopping ashwagandha abruptly has no documented rebound effect. However, a structured check-in with the prescribing clinician is appropriate.

The recommended sequence is:

1. Tell your cardiologist or internist you are taking ashwagandha (dose, brand, duration).
2. Get a fasting lipid panel, TSH, and ALT/AST within 30 days if those have not been checked in the past 3 months.
3. If you are also taking levothyroxine, alert your endocrinologist so TSH can be rechecked 6-8 weeks after any change in ashwagandha use.
4. Repeat the lipid panel and liver enzymes at 8-12 weeks after starting or stopping ashwagandha.
5. Continue alirocumab injections on schedule. Do not adjust the dose based on supplement use without a physician review.

Ashwagandha doses used in clinical trials range from 240 mg/day to 600 mg/day of standardized root extract (KSM-66 or Sensoril). Doses above 1,000 mg/day carry a higher theoretical risk for the hepatotoxicity signal and are not supported by additional clinical benefit data over 600 mg/day.